The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.
Sanofi and Regeneron Pharmaceuticals, Inc. are now well positioned to add a new blockbuster-sized indication to the labelling for their behemoth anti-inflammatory Dupixent (dupilumab), namely chronic obstructive pulmonary disease (COPD), following successful readouts for two identical Phase III trials this year.
The first of these, BOREAS, in March confounded skepticism surrounding the usefulness of biologics in this challenging respiratory condition in...
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
